Dynamic Treatment Regiments for Glucocorticoid Tapering
Status:
Recruiting
Trial end date:
2030-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to better understand how people with rheumatoid
arthritis (RA) respond to gradual dose reduction, or "tapering", of steroid medications like
prednisone. Some people with RA have symptoms when steroid dose is reduced, while others
don't. This trial will look at different patient characteristics, including levels of
inflammation in the body, differences in the way the brain processes sensory information, and
certain hormone levels, to help researchers better understand why different people have these
different responses to steroid tapering.
The hypotheses include:
- Greater or equal to ( ) 30% of participants in each arm will develop taper intolerance
(either subjective, objective, or both) during the study period
- Greater or equal to 60% of participants will reduce Glucocorticoid dose by at least 5
Milligrams per day during the study period